Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 27;39(1):93.
doi: 10.1007/s00383-023-05372-7.

Lauromacrogol foam injection under ultrasonic guidance for pediatric lip venous malformations

Affiliations

Lauromacrogol foam injection under ultrasonic guidance for pediatric lip venous malformations

Keyao Li et al. Pediatr Surg Int. .

Abstract

Objective: To evaluate the efficacy and safety of lauromacrogol foam sclerotherapy in the treatment of children with lip venous malformation.

Methods: Fifty-two children (27 males and 25 females) aged from 6 months to 17 years with lip VM who underwent lauromacrogol foam injection with ultrasonic guidance from July 2018 to December 2020 in our hospital were retrospectively recruited for this study. All the children were examined by MRI, ultrasound, blood routine and coagulation before operation. We were guided by ultrasound to locate the blood flow area (nests), injecting lauromacrogol foam to fill the venous malformation. The follow-up time was 14.31 ± 5.96 (6-24) months. Follow-up items include clinical manifestations, imaging data, efficacy and complications.

Results: This group of children was treated 3-5 times, an average of 4 times/case. The total effective rate was 90.38%. Pain in 4 cases, fever in 4 cases, infection in 2 cases, ulcer in 1 case. There were no serious complications such as cardiopulmonary accident.

Conclusion: Ultrasound guiding foam sclerotherapy with lauromacrogol is effective and safe for children with lip venous malformation.

Keywords: Children; Lauromacrogol foam; Lip venous malformation; Sclerotherapy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Hoeger PH (2021) Genes and phenotypes in vascular malformations. Clin Exp Dermatol 46(3):495–502. https://doi.org/10.1111/ced.14513 - DOI - PubMed
    1. Kunimoto K, Yamamoto Y, Jinnin M (2022) ISSVA classification of vascular anomalies and molecular biology. Int J Mol Sci. https://doi.org/10.3390/ijms23042358 - DOI - PubMed - PMC
    1. Kim H, Joh J, Labropoulos N (2022) Characteristics, clinical presentation, and treatment outcomes of venous malformation in the extremities. J Vasc Surg Venous Lymphat Disord 10(1):152–158. https://doi.org/10.1016/j.jvsv.2021.05.011 - DOI - PubMed
    1. Pahl KS, Pabon-Ramos WM, Jeng MR (2022) How we approach localized vascular anomalies. Pediatr Blood Cancer 69(Suppl 3):e29321. https://doi.org/10.1002/pbc.29321 - DOI - PubMed
    1. Carqueja IM, Sousa J, Mansilha A (2018) Vascular malformations: classification, diagnosis and treatment. Int Angiol 37(2):127–142. https://doi.org/10.23736/s0392-9590.18.03961-5 - DOI - PubMed

LinkOut - more resources